Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial

BACKGROUND: Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with a high risk of metastasis. In 2017, avelumab (anti–programmed death-ligand 1 (PD-L1)) became the first approved treatment for patients with metastatic MCC (mMCC), based on the occurrence of durable responses in...

Descripción completa

Detalles Bibliográficos
Autores principales: D'Angelo, Sandra P, Bhatia, Shailender, Brohl, Andrew S, Hamid, Omid, Mehnert, Janice M, Terheyden, Patrick, Shih, Kent C, Brownell, Isaac, Lebbé, Celeste, Lewis, Karl D, Linette, Gerald P, Milella, Michele, Georges, Sara, Shah, Parantu, Ellers-Lenz, Barbara, Bajars, Marcis, Güzel, Gülseren, Nghiem, Paul T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239697/
https://www.ncbi.nlm.nih.gov/pubmed/32414862
http://dx.doi.org/10.1136/jitc-2020-000674

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239697/
https://www.ncbi.nlm.nih.gov/pubmed/32414862
http://dx.doi.org/10.1136/jitc-2020-000674

Ejemplares similares